A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer



Status:Archived
Conditions:Liver Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:August 2009
End Date:May 2015

Use our guide to learn which trials are right for you!

Phase 2, Open-label, Single-Arm, Multi Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects With Advanced or Inoperable Hepatocellular Carcinoma


The purpose of this study is to determine whether AMG 386, in combination with Sorafenib, is
effective in the treatment of advanced or inoperable Hepatocellular cancer in subjects who
have not received any prior systemic therapy except surgery or locoregional therapy.

Disease status and disease progression will be assessed every 8 weeks. Subjects will remain
on treatment until: progressive disease by RECIST criteria; death or loss to follow-up; or
withdrawal of informed consent.



We found this trial at
5
sites
?
mi
from
San Diego, CA
Click here to add this to my saved trials
?
mi
from
Akron, OH
Click here to add this to my saved trials
?
mi
from
Bronx, NY
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
New Orleans, LA
Click here to add this to my saved trials